Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients

Basit Öğe Kaydı
dc.authorid0000-0001-7934-7039
dc.contributor.authorPeled, Nir
dc.contributor.authorGillis, Roni
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorFroesch, Patrizia
dc.contributor.authorOrlov, Sergei
dc.contributor.authorFilippova, Elena
dc.contributor.authorDemirci, Umut
dc.contributor.authorChristopoulos, Petros
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorBuğdaycı Basal, Fatma
dc.contributor.authorYılmaz, Cengiz
dc.contributor.authorFedor, Moiseenko
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorPaydaş, Semra
dc.contributor.authorGautschi, Oliver
dc.contributor.authorZırtıloğlu, Alişan
dc.contributor.authorEralp, Yeşim
dc.contributor.authorYeşil Çınkır, Havva
dc.contributor.authorSezer, Ahmet
dc.contributor.authorErman, Mustafa
dc.contributor.authorTural, Deniz
dc.contributor.authorTurna, Hande
dc.contributor.authorMazieres, Julien
dc.contributor.authorDudnik, Elizabeth
dc.contributor.authorReguart, Noemi
dc.contributor.authorCamidge, David Ross
dc.contributor.authorNg, Terry L.
dc.contributor.authorÇay Şenler, Filiz
dc.contributor.authorBeypınar, İsmail
dc.contributor.authorYazılıtaş, Doğan
dc.contributor.authorDemirkazık, Ahmet
dc.contributor.authorKaraoğlu, Aziz
dc.contributor.authorOkutur, Kerem
dc.contributor.authorCoşkun, Hasan Şenol
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorYıldız, İbrahim
dc.contributor.authorKaplan, Mehmet Ali
dc.contributor.authorÖzyılkan, Özgür
dc.contributor.authorÖztop, İlhan
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorAydın, Kübra
dc.contributor.authorAydıner, Adnan
dc.contributor.authorMeydan, Nezih
dc.contributor.authorGrinberg, Roxana Denisa
dc.contributor.authorRoisman, Laila C.
dc.date.accessioned2021-05-07T08:32:43Z
dc.date.available2021-05-07T08:32:43Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractIntroduction: Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1(+) is still pending. Here we present the largest real-world data of NSCLC patients harboring ALK/ROS1 rearrangements treated with lorlatinib.
dc.identifier.citationPeled, N., Gillis, R., Kılıçkap, S., Froesch, P., Orlov, S., Filippova, E. ... Roisman, L. C. (2021). Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients. Journal of Thoracic Oncology içinde (S656-S656. ss.).
dc.identifier.endpageS656
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue3
dc.identifier.startpageS656
dc.identifier.urihttps://hdl.handle.net/20.500.12511/6823
dc.identifier.volume16
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofJournal of Thoracic Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectROS1(+)
dc.subjectALK(+)
dc.subjectLorlatinib
dc.titleGlass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Olmez-Omer Fatih-2021.pdf
Boyut:
135.26 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu